These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 1659140)
1. Drugs of abuse and experimental autoimmune diseases. Lyman WD Adv Exp Med Biol; 1991; 288():81-92. PubMed ID: 1659140 [No Abstract] [Full Text] [Related]
2. [Demyelination and autoimmunity]. Lebar R Pathol Biol (Paris); 1987 Mar; 35(3):275-83. PubMed ID: 3295694 [TBL] [Abstract][Full Text] [Related]
3. Impact of 15-deoxyspergualin on effector cells in experimental autoimmune diseases of the nervous system in the Lewis rat. Jung S; Toyka KV; Hartung HP Clin Exp Immunol; 1994 Dec; 98(3):494-502. PubMed ID: 7527745 [TBL] [Abstract][Full Text] [Related]
4. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Steinman L Neuron; 1999 Nov; 24(3):511-4. PubMed ID: 10595504 [No Abstract] [Full Text] [Related]
5. A new primate model for multiple sclerosis in the common marmoset. 't Hart BA; van Meurs M; Brok HP; Massacesi L; Bauer J; Boon L; Bontrop RE; Laman JD Immunol Today; 2000 Jun; 21(6):290-7. PubMed ID: 10825741 [TBL] [Abstract][Full Text] [Related]
6. Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Raine CS Lab Invest; 1984 Jun; 50(6):608-35. PubMed ID: 6202955 [No Abstract] [Full Text] [Related]
8. Mouse models of autoimmune diseases. Marques A; Müller S Curr Drug Discov Technol; 2009 Dec; 6(4):262-9. PubMed ID: 20025594 [TBL] [Abstract][Full Text] [Related]
9. Animal models for autoimmune demyelinating disorders of the nervous system. Gold R; Hartung HP; Toyka KV Mol Med Today; 2000 Feb; 6(2):88-91. PubMed ID: 10652482 [TBL] [Abstract][Full Text] [Related]
10. Copolymer 1 from the laboratory to FDA. Teitelbaum D; Sela M; Arnon R Isr J Med Sci; 1997 Apr; 33(4):280-4. PubMed ID: 9347880 [No Abstract] [Full Text] [Related]
12. Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent. Bowern N; Ramshaw IA; Clark IA; Doherty PC J Exp Med; 1984 Nov; 160(5):1532-43. PubMed ID: 6333485 [TBL] [Abstract][Full Text] [Related]
13. The blood-brain barrier as target of multiple sclerosis research and therapy. Report of an international scientific meeting, Würzburg, January 23/24, 2004. Gold R; Ransohoff RM; Sandrock A; Rieckmann P J Neuroimmunol; 2004 Jul; 152(1-2):1-4. PubMed ID: 15303274 [No Abstract] [Full Text] [Related]
14. [Immunosuppressive therapy of various autoimmune diseases of the nervous system]. Neretin VIa; Odinokova VA; Kir'iakov VA; Sapfirova VA Sov Med; 1990; (12):31-5. PubMed ID: 2097756 [No Abstract] [Full Text] [Related]
15. Experimental autoimmune demyelination. Chronic relapsing models and their therapeutic implications for multiple sclerosis. Raine CS; Traugott U Ann N Y Acad Sci; 1984; 436():33-51. PubMed ID: 6085228 [No Abstract] [Full Text] [Related]